其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Tiratricol CAS Registry Number: 51-24-1 替拉曲可

CAS Name: [4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
Additional Names: 3,3',5-triiodo-4-(4-hydroxyphenoxy)phenylacetic acid; 3,5-diiodo-4-(3-iodo-4-hydroxyphenoxy)phenylacetic ac...
Literature References: Thyroid hormone analog. Prepd by iodination of 4-(4¢-hydroxyphenoxy)-3,5-diiodophenylacetic acid: Wilkinson, Biochem. J. 63, 601 (1956); Hems, GB 803149 (1958 to Glaxo); Wilkinson, GB 805761 (1958 to Nat. Res. Dev. Corp.); Meltzer et al., J. Org. Chem. 26, 1418 (1961). Clinical evaluation in thyroidectomy: S. I. Sherman, P. W. Ladenson, J. Clin. Endocrinol. Metab. 75, 901 (1992).

Carbimazole CAS Registry Number: 22232-54-8 卡比吗唑

CAS Name: 2,3-Dihydro-3-methyl-2-thioxo-1H-imidazole-1-carboxylic acid ethyl ester
Additional Names: 1-ethoxycarbonyl-3-methyl-2-thio-4-imidazoline; ethyl 3-methyl-2-thioimidazoline-1-carboxyla...
Literature References: Thyroid inhibitor. Prepn: Rimington et al., US 2671088, reissued as US RE 24505; US 2815349 (1954, 1958, 1957, all to Natl. Res. Dev. Corp.); Baker, J. Chem. Soc. 1958, 2387. Clinical efficacy in Graves' disease: J. Duprey et al., Presse Med. 17, 1124 (1988).

Posatirelin CAS Registry Number: 78664-73-0 泊替瑞林

CAS Name: N-[(6-oxo-2-piperidinyl)carbonyl]-L-leucyl-L-prolinamide
Additional Names: (2S)-N-[(1S)-1-[[(2S)-2-carbamoyl-1-pyrrolidinyl]carbonyl]-3-methylbutyl]-6-oxopipecolamide; L-6-ketopiperid...
Literature References: Thyrotropin releasing hormone analog. Prepn: L. Kisfaludy et al., DE 3024256 (1981 to Gedeon Richter); eidem, US 4386073 (1983 to Patentbureau Danubia); T. Szirtes et al., J. Med. Chem. 29, 1654 (1986). Pharmacology: M. Oka et al., Arzneim.-Forsch. 39, 297 (1989). Clinical efficacy in Alzheimer's disease: L. Parnetti et al., Acta Neurol. Scand. 92, 135 (1995).

Titanic(IV) Acid CAS Registry Number: 20338-08-3 四羟基钛

Additional Names: Orthotitanic acid; titanic hydroxide
Literature References: Ti(OH)4.xH2O. The H2O content depends upon the method and time of drying.

N-Methyl- a - L -glucosamine CAS Registry Number: 42852-95-9 a-L-葡萄糖吡喃糖,2-脱氧-2-(甲基氨基)-

CAS Name: 2-(Methylamino)-2-deoxy-a-L-glucopyranose
Percent Composition: C 43.52%, H 7.83%, N 7.25%, O 41.41%
Literature References: Together with streptose forms the streptobiosamine moiety of streptomycin: Kuehl et al., J. Am. Chem. Soc. 69, 3032 (1947). Prepn from D-glucose by Streptomyces griseus: Silverman, Rieder, J. Biol. Chem. 235, 1251 (1960); from the antibiotic, bluensomycin: Bannister, Argoudelis, J. Am. Chem. Soc. 85, 34 (1963). Review: Lemieux, Wolfrom, Adv. Carbohydr. Chem. 3, 337 (1948).

Prednicarbate CAS Registry Number: 73771-04-7 泼尼卡酯

CAS Name: (11b)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione
Additional Names: 11b,17,21-trihydroxypregna-1,4-diene-3,20-dione 17-(ethyl carbonate) 21-propio...
Literature References: Topical anti-inflammatory agent. Prepn: U. Stache et al., DE 2735110; eidem, US 4242334 (1979, 1980 both to Hoechst AG); U. Stache et al., Arzneim.-Forsch. 35, 1753 (1985). Topical and systemic activity in rats: H. G. Alpermann et al., ibid. 32, 633 (1982). Series of articles on pharmacology, pharmacokinetics and clinical efficacy: Z. Hautkrankhr. 61, Suppl. 1, 1-96 (1986).

Mometasone Furoate CAS Registry Number: 83919-23-7 糠酸莫米松

CAS Name: (11b,16a)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
Additional Names: 9,21-dichloro-11b,17-dihydroxy-16a-methylpregna-1,4-diene-3,20-di...
Literature References: Topical corticosteroid. Prepn: E. L. Shapiro, EP 57401; idem, US 4472393 (1982, 1984 both to Schering Corp.); E. L. Shapiro et al., J. Med. Chem. 30, 1581 (1987). LC-MS-MS determn in plasma: S. Sahasranaman et al., J. Chromatogr. B 819, 175 (2005). Clinical trial in psoriasis: R. S. Medansky et al., Semin. Dermatol. 6, 94 (1987); in seasonal allergic rhinitis: D. Graft et al., J. Allergy Clin. Immunol. 98, 724 (1996).

Clobetasol CAS Registry Number: 25122-41-2 氯倍他索

CAS Name: (11b,16b)-21-Chloro-9-fluoro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
Percent Composition: C 64.30%, H 6.87%, Cl 8.63%, F 4.62%, O 15.57%
Literature References: Topical corticosteroid. Prepn: Elks et al., DE 1902340; eidem, US 3721687 (1969, 1973 both to Glaxo). Review of pharmacology and clinical efficacy in skin disorders: E. A. Olsen, R. C. Cornell, J. Am. Acad. Dermatol. 15, 246-255 (1986).

Cioteronel CAS Registry Number: 89672-11-7 塞奥罗奈

CAS Name: Hexahydro-4-(5-methoxyheptyl)-2(1H)-pentalenone
Additional Names: 6-(5-methoxy-1-heptyl)bicyclo[3.3.0]octan-3-one; 2-(5-methoxyhept-1-yl)bicyclo[3.3.0]octan-7-one; X-AndronTrademarks:...
Literature References: Topically active nonsteroidal androgen-receptor blocker. Prepn: W. J. Kasha, WO 8304019 (1983 to CBD Corp.), C.A. 101, 23037k (1984). Prepn (not claimed) and use: idem, US 4689345 (1987 to CBD Corp.). Synthesis of stereoisomers: J. Mulzer et al., Tetrahedron 60, 9599 (2004). Antiandrogenic and antineoplastic activity in vitro: L. C. Ford et al., Chemotherapy (Basel) 31, 362 (1985). Series of articles on inhibition of human and microbial dihydrotestosterone-receptor binding in vitro: Rec. Adv. Chemother., Proc. 14th Int. Congr. Chemother. Antimicrob. Sect. 1 (Univ. Tokyo Press, Tokyo, 1985) pp 261-270; 273-274. Cutaneous metabolism in humans: R. A. de Zeeuw et al., Pharm. Res. 7, 638 (1990). Clinical pharmacokinetics: J. W. Wiechers et al., Int. J. Pharm. 65, 77 (1990).

Edotecarin CAS Registry Number: 174402-32-5 12-(β-D-葡萄吡喃基)-2,10-二羟基-6-[2-羟基-1-(羟甲基)乙基氨基]-6,7,12,13-四氢-5H-吲哚[2,3-a]吡咯罗[3,4-c]卡巴唑-5,7-二酮

CAS Name: 12-b-D-Glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dionePercent Composition: C 57.24%, H 4.64%...
Literature References: Topoisomerase I inhibitor that induces single strand DNA cleavage. Prepn: K. Kojiri et al., EP 760375; eidem, US 5922860 (1997, 1999 both to Banyu Pharm.); M. Ohkubo et al., Bioorg. Med. Chem. Lett. 9, 3307 (1999). Synthesis: A. Akao et al., Tetrahedron 57, 8917 (2001). Mechanism of action study: T. Yoshinari et al., Cancer Res. 59, 4271 (1999). In vivo antitumor activity: H. Arakawa et al., Jpn. J. Cancer Res. 90, 1163 (1999). LC/MS/MS determn in plasma: A. Q. Wang et al., Rapid Commun. Mass Spectrom. 16, 975 (2002). Review of development: W. A. Denny, IDrugs 7, 173-177 (2004); and clinical experience: M. W. Saif, R. B. Diasio, Clin. Colorectal Cancer 5, 27-36 (2005).